Literature DB >> 30026301

HSP90 inhibition without heat shock response.

John C Byrd1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30026301      PMCID： PMC6053952          DOI： 10.1182/blood-2018-05-850271

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Authors:  Erin Hertlein; Amy J Wagner; Jeffrey Jones; Thomas S Lin; Kami J Maddocks; William H Towns; Virginia M Goettl; Xiaoli Zhang; David Jarjoura; Chelsey A Raymond; Derek A West; Carlo M Croce; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

2.  Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Melissa L Johnson; Helena A Yu; Eric M Hart; Bing Bing Weitner; Alfred W Rademaker; Jyoti D Patel; Mark G Kris; Gregory J Riely
Journal:  J Clin Oncol       Date:  2015-04-13       Impact factor: 44.544

3.  Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Authors:  Jeffrey R Infante; Glen J Weiss; Suzanne Jones; Raoul Tibes; Todd M Bauer; Johanna C Bendell; James M Hinson; Daniel D Von Hoff; Howard A Burris; Everardus O Orlemans; Ramesh K Ramanathan
Journal:  Eur J Cancer       Date:  2014-09-25       Impact factor: 9.162

4.  Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.

Authors:  J E Lancet; I Gojo; M Burton; M Quinn; S M Tighe; K Kersey; Z Zhong; M X Albitar; K Bhalla; A L Hannah; M R Baer
Journal:  Leukemia       Date:  2010-01-28       Impact factor: 11.528

5.  Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

Authors:  Y Shiotsu; L M Neckers; I Wortman; W G An; T W Schulte; S Soga; C Murakata; T Tamaoki; S Akinaga
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  Rational design of shepherdin, a novel anticancer agent.

Authors:  Janet Plescia; Whitney Salz; Fang Xia; Marzia Pennati; Nadia Zaffaroni; Maria Grazia Daidone; Massimiliano Meli; Takehiko Dohi; Paola Fortugno; Yulia Nefedova; Dmitry I Gabrilovich; Giorgio Colombo; Dario C Altieri
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

7.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors:  Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

8.  Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.

Authors:  Alison R Walker; Rebecca Klisovic; Jeffrey S Johnston; Yao Jiang; Susan Geyer; Cheryl Kefauver; Philip Binkley; John C Byrd; Michael R Grever; Ramiro Garzon; Mitch A Phelps; Guido Marcucci; Kristie A Blum; William Blum
Journal:  Leuk Lymphoma       Date:  2013-01-24

9.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors:  Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

10.  Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.

Authors:  Cong Peng; Julia Brain; Yiguo Hu; Ami Goodrich; Linghong Kong; David Grayzel; Roger Pak; Margaret Read; Shaoguang Li
Journal:  Blood       Date:  2007-03-29       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.